To determine whether blocking hyperactivated MEK/ERK and/or NF-κB signaling inhibits NPmut AML cell growth in vitro, we cultured mouse NPmut-AML cells in the presence of the FDA-approved MEK inhibitor trametinib (Tra) (49) and/or IKK-16. Here, MAP2K7 is linked to acute myeloid leukemia.